PHAT · Phathom Pharmaceuticals, Inc.

NasdaqHealthcareBiotechnology

Phathom Pharmaceuticals Inc Operates As A Clinical-Stage Biopharmaceutical Company. The Firm Is Focused On Developing And Commercializing Novel Treatments For Gastrointestinal, Or Gi, Diseases. Its Product Comprises Vonoprazan, An Oral Small-Molecule Potassium Competitive Acid Blocker Medicine That Blocks Acid Secretion In The Stomach. Vonoprazan Shows Rapid, Potent, And Durable Anti-Secretory Effects And Has Demonstrated Clinical Benefits In The Treatment Of Gastroesophageal Reflux Disease, And In Combination With Antibiotics For The Treatment Of Helicobacter Pylori Infection.

HealthcareNasdaqUS

$12.32

+162.7% latest move

Price & move as of the most recent catalyst (Jun 5) — not a live quote.

FLOAT

56.0M

FREE FLOAT %

69%

SHARES O/S

80.9M

MARKET CAP

$576.8M

EXCHANGE

Nasdaq

COUNTRY

PHAT Catalyst History

Regulatory and ClinicalJun 5, 2025 · 6:39pm ET

PHATPhathom Pharmaceuticals, Inc.

FDA Grants Phathom Pharmaceuticals 10 Years of Exclusivity for VOQUEZNA Tablets

Regulatory exclusivity extends until May 3, 2032.

Be early on the next PHAT spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →